CBD

FDA Response on CBD Fails Consumers and Industry and Highlights Agency’s Four Years of Inaction

CRN expressed dismay today about FDA’s denial of its 2020 citizen petition calling on the agency to create a regulatory pathway to legally market dietary supplements containing hemp-derived cannabidiol (CBD) and the agency’s separate announcement that FDA “has concluded a new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks.”